New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.

@article{Lencioni2013NewDS,
  title={New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.},
  author={Riccardo A Lencioni},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 6},
  pages={1312-4}
}
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice. 
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma

  • JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu
  • J Natl Cancer Inst 2008;100:698-711
  • 2008
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…